EXPD vs REGN · P/E 26, rev $10.60B vs P/E 14, rev $14.34B
Expeditors International of Washington, Inc. (EXPD) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Expeditors International of Washington, Inc. (EXPD) is a integrated freight & logistics company listed on NYSE.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported EXPD revenue for 2024-12-31 was $10.60B. Net income was $811.6M. Revenue was up 14.0% from 2023-12-31 to 2024-12-31. EXPD currently screens at market cap $21.01B and trailing P/E 26.0.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
EXPD currently screens at market cap $21.01B and trailing P/E 26.0. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the EXPD and REGN stock pages for the full models.
Not investment advice.